Sch-27899 (Schering-Plough Corp).
Sch27899 (Ziracin) is an oligosaccharide antibiotic under development by Schering-Plough as a potential treatment for Gram-positive bacterial infection, including vancomycin- and methicillin-resistant bacteria. It is being evaluated in phase III clinical trials. Sch-27899 is a member of the naturally occurring class of everninomicins and was isolated from Micromonospora. Sch-27899 and the Micromonospora strain producing it were first disclosed in US04597968. The cyclodextrin complex, which overcomes the toxicity problems of Sch27899, is claimed in EP00538011.